Orion Oyj (LON:0M2O)

Market Cap	8.02B
Revenue (ttm)	1.44B
Net Income (ttm)	324.02M
Shares Out	n/a
EPS (ttm)	2.31
PE Ratio	24.75
Forward PE	19.00
Dividend	1.37 (2.08%)
Ex-Dividend Date	Apr 4, 2025

Volume	63,319
Average Volume	25,345
Open	65.68
Previous Close	65.53
Day's Range	65.25 - 66.15
52-Week Range	41.43 - 72.00
Beta	0.35
RSI	43.60
Earnings Date	Oct 28, 2025

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid art...

• Industry: Pharmaceutical Preparations
• Founded: 1917
• Employees: 3,880
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0M2O

Financial Performance

In 2024, Orion Oyj's revenue was 1.54 billion, an increase of 29.65% compared to the previous year's 1.19 billion. Earnings were 329.90 million, an increase of 52.17%.

Financial numbers in EUR